Get Our FREE Newsletter

Sign Up

Vaccine biotech Icosavax sets terms for $150 million IPO

Spread the love

Icosavax, a Phase 1 biotech developing vaccines for respiratory diseases, announced terms for its IPO on Thursday.The Seattle, WA-based company plans to raise $150 million by offering 10 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Icosava

This post was originally published on this site